Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
1.970
+0.040 (2.07%)
At close: Aug 13, 2025, 4:00 PM
1.950
-0.020 (-1.02%)
Pre-market: Aug 14, 2025, 9:07 AM EDT
Gossamer Bio Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Gossamer Bio stock ranges from a low of $5.00 to a high of $11. The average analyst price target of $8.50 forecasts a 331.47% increase in the stock price over the next year.
Price Target: $8.50 (+331.47%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Gossamer Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +153.81% | Aug 6, 2025 |
| Scotiabank | Scotiabank | Buy Initiates $11 | Buy | Initiates | $11 | +458.38% | Jul 14, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $7 → $8 | Strong Buy | Maintains | $7 → $8 | +306.09% | May 16, 2025 |
| Wedbush | Wedbush | Buy Reiterates $4 | Buy | Reiterates | $4 | +103.05% | May 16, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $8 → $7 | Strong Buy | Maintains | $8 → $7 | +255.33% | Apr 17, 2025 |
Financial Forecast
Revenue This Year
29.88M
from 114.70M
Decreased by -73.95%
Revenue Next Year
48.99M
from 29.88M
Increased by 63.97%
EPS This Year
-0.69
from -0.25
EPS Next Year
-0.51
from -0.69
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 62.8M | 126.4M | 236.4M | ||
| Avg | 29.9M | 49.0M | 141.6M | ||
| Low | 9.7M | n/a | 51.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -45.3% | 323.1% | 382.6% | ||
| Avg | -74.0% | 64.0% | 189.1% | ||
| Low | -91.6% | - | 4.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.53 | -0.12 | 0.32 | ||
| Avg | -0.69 | -0.51 | -0.16 | ||
| Low | -0.78 | -0.79 | -0.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.